<DOC>
	<DOCNO>NCT00677365</DOCNO>
	<brief_summary>Patients cystic fibrosis ( CF ) suffer chronic infection low respiratory tract cause one multiple bacteria , include Pseudomonas aeruginosa , particularly problematic eradicate implicate major cause morbidity mortality CF patient . Aerosol delivery antibiotic directly lung increase local concentration antibiotic site infection result improve antimicrobial effect compare systemic administration . Bacterial resistance current aerosol antibiotic treatment indicate need improved therapy treat CF patient pulmonary infection cause multi-drug resistant Pseudomonas aeruginosa bacteria . High concentration MP-376 deliver directly lung project antimicrobial effect even resistant organism .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy MP-376 Given 28 Days Cystic Fibrosis ( CF ) Patients</brief_title>
	<detailed_description>This trial double-blind , placebo-controlled study evaluate safety , tolerability efficacy levofloxacin administer MP-376 three dosage regimen give 28 day aerosol route CF patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<criteria>Inclusion Criteria ( select ) : &gt; 16 year age Confirmed Diagnosis Cystic Fibrosis Positive sputum culture P. aeruginosa within past 18 month Patients able elicit forced expiratory volume 1 second ( FEV1 ) &gt; /= 25 % &lt; /= 85 % predict value screen Have receive least 3 course inhaled antimicrobial precede 12 month Clinically stable change health status within last 30 day Able reproducibly produce sputum perform spirometry Exclusion Criteria ( select ) : Use nebulized systemic antibiotic within 30 day prior baseline History hypersensitivity fluoroquinolones intolerance aerosol medication Evidence acute upper within 10 day low respiratory infection within 30 day prior dose Creatine clearance &lt; 50mg/ml , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) total bilirubin &gt; /= 3 x upper limite normal ( ULN ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>